4.3 Article

An immunohistochemical panel of three small ubiquitin-like modifier genes predicts outcomes of patients with triple-negative breast cancer

期刊

GLAND SURGERY
卷 10, 期 3, 页码 1067-1084

出版社

AME PUBL CO
DOI: 10.21037/gs-21-37

关键词

Triple-negative breast cancer (TNBC); small ubiquitin-like modifier (SUMO); prognostic; chemotherapy; MYC

类别

资金

  1. Natural Science Foundation of Fujian Province [2017J01200, 2020J01311402]
  2. Innovation of Science and Technology of Fujian Province [2019Y9054]
  3. National Natural Science Foundation of China [81672817]
  4. National Science Foundation for Young Scientists of China [82003095]
  5. Fujian Provincial Key Laboratory of Hepatic Drug Research [KFLX2020001]

向作者/读者索取更多资源

Elevated levels of SUMO1/2/3 were associated with poorer survival outcomes for TNBC patients. A classifier was developed based on this association to predict chemotherapy response, and a nomogram was created to identify patients who may benefit from chemotherapy. The study also suggested that the activation of the SUMOylation pathway in TNBC might be induced by MYC signaling.
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive disease. Developing new candidate biomarkers for chemotherapy response and possible therapeutic targets has become an urgent clinical need. Small ubiquitin-like modifiers (SUMOs) mediate post-translational modifications (SUMOylation) has been shown to be involved in numerous biological processes. However, the role of SUMOylation in TNBC has yet to be elucidated. Method: The mRNA expression of SUMO1/2/3 was analyzed by the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus database (GEO) databases (N=412). We also evaluated the SUMO1/2/3 protein expression in 212 TNBC patients using immunohistochemical (IHC) staining method. A classifier with Least absolute shrinkage and selection operator (LASSO) Cox regression model was then built based on the associations between the expression of SUMO1/2/3 proteins and the disease-free survival (DFS) of TNBC patients. Results: Elevated SUMO1/2/3 levels were indicated to be associated with a poorer overall survival (OS) and DFS for TNBC patients. With the LASSO model, we built a classifier based on the IHC scores of SUMO1/2/3 proteins and named it the `SB classifier'. Patients with SB classifier-defined high score were found to have an unfavorable response to chemotherapy [hazard ratio (HR) 4.04, 95% confidence interval (CI): 2.14-7.63; P<0.0001]. A nomogram was then developed to identify which patients might benefit from chemotherapy. Finally, our results also suggested that the activation of SUMOylation pathway in TNBC might be induced by MYC signaling. Conclusions: We constructed a reliable prognostic and predictive tool for TNBC patients treated with chemotherapy, which could facilitate individualized counseling and management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据